Rallybio (33M0) Stock Overview

A clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. More details

33M0 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 97.8% below our estimate of its fair value

Earnings are forecast to grow 67.56% per year

Became profitable this year

Risk Analysis

Makes less than USD$1m in revenue ($646K)

Shares are highly illiquid

High level of non-cash earnings

Does not have a meaningful market cap (€77M)

33M0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW460,775 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

460,775 investors already sharing narratives

View all narratives

Rallybio Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Rallybio
Historical stock prices
Current Share Price	US$14.00
52 Week High	US$14.40
52 Week Low	US$13.40
Beta	-0.86
1 Month Change	-1.41%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	3.70%

Recent updates

Shareholder Returns

	33M0	DE Biotechs	DE Market
7D	0.7%	-1.7%	-0.7%
1Y	n/a	4.0%	2.6%

Return vs Industry: Insufficient data to determine how 33M0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 33M0 performed against the German Market.

Price Volatility

Is 33M0's price volatile compared to industry and market?
33M0 volatility
33M0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	5.1%
10% most volatile stocks in DE Market	13.0%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 33M0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 33M0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	7	Steve Uden	www.rallybio.com

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia.

Rallybio Corporation Fundamentals Summary

How do Rallybio's earnings and revenue compare to its market cap?
33M0 fundamental statistics
Market cap	€77.31m
Earnings (TTM)	€39.01m
Revenue (TTM)	€553.23k

2.0x

P/E Ratio

139.7x

P/S Ratio

Is 33M0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
33M0 income statement (TTM)
Revenue	US$646.00k
Cost of Revenue	US$17.19m
Gross Profit	-US$16.54m
Other Expenses	-US$62.09m
Earnings	US$45.55m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	8.58
Gross Margin	-2,560.68%
Net Profit Margin	7,051.24%
Debt/Equity Ratio	0%

How did 33M0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/20 13:16
End of Day Share Price	2026/08/19 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rallybio Corporation is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jonathan Wolleben	Citizens JMP Securities, LLC
Eun Kyung Yang	Jefferies LLC
Ritu Baral	TD Cowen

Rallybio CorporationDB:33M0 Stock Report